Please ensure Javascript is enabled for purposes of website accessibility

Why CVS Health Corporation Stock Rose 16% in August

By Jeremy Bowman – Sep 6, 2018 at 1:14PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares of the pharmacy leader gained as it posted impressive earnings results.

What happened

Shares of CVS Health Corporation (CVS -0.07%) were looking fit last month as the drugstore chain rose on a strong earnings report and as concerns about competition from Amazon seemed to ebb.

The stock finished August up 16% according to data from S&P Global Market Intelligence.

A pharmacist hands some pills to a customer.

Image source: Getty Images.

As you can see from the chart below, the surge came during the middle of the month following its second-quarter earnings report.

CVS Chart

CVS data by YCharts.

So what

Shares of the country's No. 1 pharmacy chain rose 4% on August 8 as the company posted impressive second-quarter results. Same-store prescription volume rose 9.5%, a key driver of the underlying business, and revenue increased 2.2% to $46.7 billion, topping estimates at $46.34 billion. Meanwhile, same-store sales were up 5.9%, and pharmacy same-store sales increased 8.3%, though front-end comps were down 1%.

Gross margin improved modestly in the quarter, which helped drive an adjusted profit per share of $1.69, though that excludes a $3.9 billion goodwill impairment charge relating to the long-term-care business. The adjusted profit beat analyst expectations at $1.61.

Meanwhile, optimism for the company's pending merger with Aetna seemed to grow, as did the belief that Amazon, following its June acquisition of PillPack, was not as big a threat as some had earlier thought.

Now what 

CVS got some more good news early in September on a report that the Justice Department is nearing approval of the merger with Aetna. According to the Wall Street Journal, permission could come within the next few weeks. 

The drugstore chain also raised its full-year EPS guidance from $6.98-$7.08, from $6.87-$7.08, and it sees adjusted EPS of $1.68-$1.73 for the current quarter, slightly below analyst estimates of $1.75 at the time.

Still, the major driver of the stock over the near term should be the pending approval of its merger with Aetna. CVS shares have risen before on indications that the combination will go through and are likely to do the same if it gains full approval.


John Mackey, CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Jeremy Bowman has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Amazon. The Motley Fool recommends CVS Health. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

CVS Health Stock Quote
CVS Health
$100.45 (-0.07%) $0.07
Amazon Stock Quote
$120.95 (-0.12%) $0.14
Aetna Inc. Stock Quote
Aetna Inc.

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/06/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.